Latest news with #PeripheralArteryDisease
Yahoo
3 days ago
- Health
- Yahoo
Breakthrough procedure helps prevent amputations for Sacramento area patients
( — A breakthrough surgery helping save limbs and lives took place in Sacramento on Wednesday morning. The procedure aims to treat people suffering from Peripheral Artery Disease. PAD is a serious and rarely-treated circulatory condition that restricts blood flow to the limbs due to narrowed blood vessels. It kills more people than breast, colon, and prostate cancer combined. 'Plaque that builds up in these arteries causes not only hardening of the arteries but also plaque in these blood vessels,' said Dr. Inder Singh, an interventional cardiovascular specialist at TLC Vascular. When blood can't flow properly, minor wounds can become dangerous. They can lead to infection and, in some cases, amputation. Michaels Distributing Center in San Joaquin County set to close, affecting over 200 jobs 'If they get an injury or they get a wound or they get a scratch, those will not heal because they don't have enough, adequate perfusion to heal those wounds,' Dr. Singh said. Helping to change patient outcomes, Dr. Singh is now performing a first-of-its-kind procedure using a newly FDA-cleared removable stent called SPUR. 'The idea with it is that basically that kind of treatment that deep penetrates into the tissue and treats it, it will prevent future closure or at least prolong the time from when the blood vessels close,' said Dr. Singh. 'Enabling the patients to be able to heal their wounds, which is really the main outcome we're looking for.' is the first in the Sacramento area to use SPUR, designed specifically for the small, fragile arteries below the knee. Unlike a traditional stent, the spur temporarily holds the vessel open and then is removed, leaving nothing behind. Charges filed against former Cal Fire employee in child pornography case 'We can see somebody on an outpatient basis one day and actually fix a problem rather than put a band-aid on, you know, the incorrect problem,' said Shelby Adney, a nurse practitioner at TLC Vascular. It's an innovative procedure now preventing amputations, healing wounds, and maintaining patients' normal lives. 'Once you can preserve that and heal their wounds… they get their life back,' Dr. Singh said. 'They're ambulatory. They can spend time with their family. You can do a lot of things that most people expect to do.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
03-04-2025
- Business
- Yahoo
Vascular Closure Device Market Size Projected to Grow to USD 3.03 Billion by 2030, Fuelled by Cardiovascular Disease Prevalence and Minimally Invasive Trends
The global vascular closure device market share is projected to grow from USD 1.73 billion in 2022 to USD 3.03 billion by 2030, driven by the increasing prevalence of cardiovascular diseases and the rising demand for minimally invasive procedures. Innovations in device technologies, such as collagen-based and mechanical devices, are boosting market growth. North America leads the market, while Asia Pacific is expected to register the highest growth during the forecast period. US & Canada, April 03, 2025 (GLOBE NEWSWIRE) -- US & Canada, Apr, 01, 2025 (GlobeNewswire) -- According to a comprehensive report from The Insight Partners, 'Vascular Closure Device Market Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report', The vascular closure device market size is projected to reach US$ 3.03 billion by 2030 from US$ 1.73 billion in 2022. The market is expected to register a CAGR of 7.1% in 2022–2030To explore the valuable insights in the Vascular Closure Devices Market report, you can easily download a sample PDF of the report- The global vascular closure devices market is growing significantly with the increasing prevalence of cardiovascular diseases. The vascular closure devices market is segmented on the basis of product type, access, procedure, and end user. The report runs an in-depth analysis of market trends, key players, and future opportunities. Competitive Strategy and Development Key Players: A few of the major companies operating in the vascular closure devices market are Cordis Corp., Transluminal Technologies LLC, Vasorum Ltd, Haemonetics Corp., Abbott Laboratories, Becton Dickinson and Co, Cardinal Health Inc, ENDOCOR GmbH & CO KG, and Medtronic Plc. Trending Topics: Cardiovascular Devices, Catheterization, Interventional Cardiology, Peripheral Artery Disease (PAD), Hemostasis Devices, Endovascular Devices, Minimally Invasive Surgery (MIS), Etc. Global Headlines on Vascular Closure Devices Market Cordis Awarded Vascular Closure Devices Agreement with Premier, Inc. for MYNX CONTROL VENOUS Vascular Closure Device PATCH Clinical Study of PerQseal Vascular Closure System Reaches 100-Patient Milestone Vivasure Medical to Unveil US Pivotal Data for PerQseal Elite Vascular Closure System Vascular Closure Devices Market Overview of Report Findings 1. Market Growth: The global vascular closure device market is expected to reach US$ 2.80 billion in 2030 from US$ 3.03 billion in 2022. The market is estimated to grow at a CAGR of 7.1% from 2022 to 2030. The growth of the market is attributed to the increasing prevalence of cardiovascular diseases and burgeoning demand for minimally invasive devices. However, the risk of infection related to vascular closure devices hinders the market growth. 2. Increasing Prevalence of Cardiovascular Diseases: Cardiovascular diseases, including coronary artery disease, heart attack, stroke, and peripheral artery disease, are among the major causes of mortality worldwide. The burgeoning prevalence of these diseases has resulted in an upsurge in interventional procedures such as angioplasty, catheterization, and stenting, all of which necessarily require successful post-procedure vascular closure techniques. As per the World Health Organization (WHO) 2021, cardiovascular diseases cause nearly 17.9 million deaths each year, which is approximately 32% of the total deaths in the world. As per the CDC, in the US alone, 1 in 20 adults aged 20 or more have coronary artery disease (CAD), indicating a huge patient base that needs interventional interventions. With the growing rate of interventional cardiology procedures such as catheterizations and angioplasties, there is an increasing need for reliable vascular closure mechanisms. As per the report Cardiac Catheterization Risks and Complications, published in 2023, over 1,000,000 cardiac catheterization procedures are performed annually in the US. The procedures usually need closure devices to close the site of access and mitigate complications such as bleeding, hematomas, and infections. 3. Rising Preference for Minimally Invasive Procedures: The use of minimally invasive procedures has grown tremendously in recent decades, as patients are looking for interventions that carry less risk, have faster recovery times, and cause fewer scars. Minimally invasive procedures such as catheterization, coronary angioplasty, and stent placements have gained popularity. Vascular closure devices are important in maintaining the safety and efficacy of such interventions, as most of these interventions might need a proper closing of vascular access sites. a. Collagen-Based Devices: Collagen-based closure devices present a minimally invasive alternative to conventional products. They establish instant hemostasis with fewer complications, diminishing the requirement for manual compression. The technology finds great application in patients who undergo coronary interventions wherein swift recovery is a prime requirement. b. Mechanical and Suture-Based Devices: Technologies in mechanical and suture-based devices provide shorter closure times, reduced complications, and better patient outcomes. Such technologies are especially relevant in high-volume centers and interventional centers, where the need for efficient and safe vascular access closure is increasing. 4. Geographical Insights: In 2022, North America led the market with a substantial revenue share, followed by Europe and Asia Pacific, respectively. Asia Pacific is expected to register the highest CAGR in the vascular closure devices market during the forecast period. Market Segmentation The vascular closure device market, by product type, is segmented into active approximators, passive approximators, and external hemostatic devices. The passive approximators segment held the largest share of the market in 2022, and it is anticipated to register the highest CAGR in the market during 2022–2030. Based on access, the vascular closure device market has been segmented into femoral access and radial access. The femoral access segment held a larger share of the market in 2022, and radial access is expected to register a higher CAGR in the market during 2022–2030. Based on procedure, the vascular closure device market is segmented into interventional radiology, interventional cardiology, and endovascular surgeries. The interventional cardiology segment held the largest share of the market in 2022. The same segment is expected to register the highest CAGR in the market during 2022–2030. The vascular closure device market, by end user, is segmented into hospitals, ambulatory surgical centers, and others. The hospital segment held the largest share of the market in 2022. However, the ambulatory surgical centers segment is expected to register the highest CAGR in the market during 2022–2030. The vascular closure devices market is segmented into five major regions: North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America. Conclusion The vascular closure devices market is expected to witness rapid growth owing to the rising incidence of cardiovascular diseases, surging demand for interventional treatments involving efficient closure methods, and increasing adoption of minimally invasive procedures. As healthcare practitioners and patients value the benefits of quicker recovery times, lower complication rates, and enhanced safety procedures, the adoption of cutting-edge vascular closure devices would continue to rise in the coming years as well. The vascular closure devices market is expected to grow further with continuous innovations and a strong new technology pipeline to address the changing requirements of the healthcare sector. The report from The Insight Partners lists several stakeholders—including manufacturers, healthcare providers, distributors and suppliers, and regulatory bodies—along with valuable insights on how to successfully navigate this evolving market landscape and unlock new opportunities. Related Reports- Cardiovascular Devices Market Key Players and Opportunities by 2031 Minimally Invasive Surgery Market Outlook, Dynamics and Strategic Insights by 2031 Interventional Cardiology Devices Market Share, Size, Trends, and Forecast by 2031 Endovascular Treatment Devices Market Overview, Growth, and Trends (2021-2031)About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Défense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Us: If you have any queries about this report or if you would like further information, please contact us: Contact Person: Ankit MathurE-mail: +1-646-491-9876 Press Release- in to access your portfolio
Yahoo
28-01-2025
- Business
- Yahoo
Cagent Vascular Initiates the Serranator® POINT FORCE Observational Registry
Study Will Enroll a Minimum of 500 Patients Across 30 United States Centers, Demonstrating the Benefits of Cagent's Unique Serration Balloon Angioplasty Technology in Real-World Clinical Cases WAYNE, Penn., January 28, 2025--(BUSINESS WIRE)--Cagent Vascular, Inc., the exclusive developer of serration technology for vessel dilation in endovascular interventions, today announced the start of the POINT FORCE Registry, a post-market clinical follow-up study of the Serranator® PTA Serration Balloon Catheter. This prospective, multicenter, single-arm study will enroll a minimum of 500 subjects at up to 30 centers in the United States. The objective of this study is to evaluate the safety and efficacy, under local standard of care, of Serration Angioplasty for the treatment of Peripheral Artery Disease (PAD) throughout the entire leg. The primary endpoint for this study is Device Success, defined as the achievement of successful delivery, balloon inflation and deflation, and retrieval of the study device with a post- Serranator® residual stenosis of ≤30%, as assessed by an independent angiographic core lab. Yale Cardiovascular Research Group in New Haven, CT, will serve as the corelab for this study. Led by national co-principal investigators S. Jay Mathews, MD, MS, Director Cardiac Catheterization Laboratory, PERT & Structural Heart at Manatee Memorial Hospital in Bradenton, FL and Michael Siah, MD, Director of Limb Salvage at University of Texas Southwestern (UTSW) Medical Center in Dallas, TX, this registry will build the body of clinical evidence for Serration Angioplasty. The first POINT FORCE patient was enrolled at UTSW by Dr. Siah. "We're excited to launch the POINT FORCE registry with the initial enrollment here at UTSW," Dr. Siah said, "Serranator® is a key part of our ATK and BTK treatment algorithm, and our team is eager to analyze this large, corelab-adjudicated dataset to capture the results of treating with Serranation across a wide spectrum of treatment strategies and clinical presentations." "We know from prior corelab-adjudicated studies that Serranator® provides an efficacious result for patients, with a very low rate of complication and mitigated recoil," stated Dr. Mathews, "What we endeavor to understand In POINT FORCE is the role Serranation can play in routine clinical practice. We anticipate reviewing Iliac, Fem-Pop, Infra-Pop, and Infra-Malleolar vessel territories, along with AV Access." Brian Walsh, Chairman and CEO of Cagent Vascular, added, "Despite having performed over 20,000 procedures, Serranator® remains a new and disruptive PAD therapy. We expect POINT FORCE will illuminate the benefits of Serranation and help share the impact in all common clinical algorithms. We're excited to get started and grateful for the support of our PIs and all participating centers." About Cagent Vascular, Inc. For more information, visit The Serranator® is an FDA-cleared, novel balloon using proprietary stainless steel micro-serration technology, designed to create linear, interrupted scoring along the endoluminal surface. With 1,000x more point force compared with plain-old balloon angioplasty, serration occurs during slow-and-low balloon inflation and is designed to aid arterial expansion, effectively achieving luminal gain in all lesion morphologies. View source version on Contacts Cagent Communications and Media Contact:Lauren Pfeiffer+1 610-688-2006LPfeiffer@ Sign in to access your portfolio
